Head to head
Grail vs Thermo Fisher Scientific
Side-by-side on the measures that matter, with a plain-English read. Full detail: GRAL · TMO
GRAL
Grail
99.25-5.33%
1-year price shape — +16% over the period
Quant Rating C · 56/100
vs
TMO
Thermo Fisher Scientific
669.54-2.79%
1-year price shape — +17% over the period
Quant Rating C · 61/100
1-year performance, rebased to 100
Thermo Fisher Scientific edges it on the scoreable measures. Thermo Fisher Scientific has the highest Quant Rating (61); Thermo Fisher Scientific has done best over the past year (+17%); Thermo Fisher Scientific pays the highest dividend yield.
| GRAL | TMO | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 99.25 | 669.54 |
| Change today | -5.33% | -2.79% |
| 1-year return | +15.9% | +17.2% |
| Market cap | $4.46B | $248.08B |
| 52-week range | 41.50 – 166.48 | 434.50 – 727.56 |
| Valuation | ||
| P/E (TTM) | -10.76 | 35.31 |
| P/E percentile, own 5-yr range | 6th | 89th |
| P/B | 1.82 | 4.53 |
| Dividend yield | 0.00% | 0.27% |
| Profitability & growth | ||
| EPS (TTM) | -11.11 | 17.74 |
| Net profit (TTM) | $-499.53M | $6.57B |
| Revenue (TTM) | $166.60M | $47.35B |
| Provider revenue period date | 2026-09-29 | 2026-09-25 |
| Revenue growth (YoY) | +3.7% | +9.1% |
| Gross margin | -33.7% | 41.1% |
| Operating margin | -332.0% | 18.7% |
| Net margin | -243.8% | 14.9% |
| Free cash flow (TTM) | $-312.00M | $7.60B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-25 |
| Ownership & sentiment | ||
| Institutional ownership | 90.9% | 94.1% |
| Insider activity (12mo) | 19 buy / 30 sell | 20 buy / 30 sell |
| Short interest (% of float) | 17.9% | 1.3% |
| Analyst consensus | 75% buy / 25% hold (8) | 88% buy / 12% hold (16) |
| Analyst price target | $146 (+47%) | $778 (+16%) |
| StockVane view | ||
| StockVane Quant Rating | C (56) | C (61) |
| Company | ||
| Employees | 910 | 125,000 |
| Founded | 2015 | 1956 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.